Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors

Asaoka,Daisuke; Nagahara,Akihito; Hojo,Mariko; Matsumoto,Kenshi; Ueyama,Hiroya; Matsumoto,Kohei; Izumi,Kentaro; Takeda,Tsutomu; Komori,Hiroyuki; Akazawa,Yoichi; Shimada,Yuji; Osada,Taro; Watanabe,Sumio

doi:10.3892/br.2016.710

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors

Authors:
- Daisuke Asaoka
- Akihito Nagahara
- Mariko Hojo
- Kenshi Matsumoto
- Hiroya Ueyama
- Kohei Matsumoto
- Kentaro Izumi
- Tsutomu Takeda
- Hiroyuki Komori
- Yoichi Akazawa
- Yuji Shimada
- Taro Osada
- Sumio Watanabe
View Affiliations

Affiliations: Department of Gastroenterology, School of Medicine, University of Juntendo, Tokyo 113‑8421, Japan, Department of Gastroenterology, Juntendo University Shizuoka Hospital, Shizuoka 410‑2295, Japan
Published online on: June 30, 2016 https://doi.org/10.3892/br.2016.710
Pages: 165-170
Copyright: © Asaoka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been indicated that proton pump inhibitor (PPI) use is associated with a loss of the anti‑fracture efficacy of alendronate (AD). However, there are few prospective studies that have investigated the efficacy of AD on lumbar bone mineral density (BMD) in osteoporotic patients who are using PPIs. Thus, the aim of the present study was to investigate the efficacy of alfacalcidol (AC) and AD on lumbar BMD in osteoporotic patients using PPIs. A prospective, randomized, active control study enrolled such osteoporotic patients (age, ≥50 years). The patients were randomly assigned to receive AC (1 µg/day) or AD (35 mg/week) and were followed up for one year. Patient profiles were maintained, and lumbar BMD, bone‑specific alkaline‑phosphatase (BAP) and collagen type‑I cross‑linked N‑telopeptide (NTX), upper gastrointestinal endoscopy results, and the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) were evaluated. Percentage changes in lumbar BMD, NTX, BAP, and change in FSSG score from baseline to the end of one year of treatment were investigated. Sixteen patients were eligible for analysis (eight assigned to receive AC, eight assigned to receive AD). The percentage change in lumbar BMD from baseline to the end of treatment was ‑0.4±4.0% for the AC group vs. 6.8±6.3% for the AD group (P=0.015). No significant percentage change of BAP and NTX between the two groups was observed. Subsequent to one year of treatment, the FSSG score did not change from the baseline values for either study group, and no new bone fractures or esophagitis were observed in either group of patients. The findings demonstrated that in osteoporotic patients using concomitant PPIs, there was a greater increase in lumbar BMD after one year of treatment with AD compared with AC. However, the number of study subjects was small; thus, further, large prospective studies are required to determine the effect of AD in osteoporotic patients using concomitant PPIs.

View Figures

View References

1	Iki M: Epidemiology of osteoporosis in Japan. Clin Calcium. 22:797–803. 2012.(In Japanese). PubMed/NCBI
2	Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, et al: The Alendronate Phase III Osteoporosis Treatment Study Group: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1437–1443. 1995. View Article : Google Scholar : PubMed/NCBI
3	de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H and Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med. 335:1016–1021. 1996. View Article : Google Scholar : PubMed/NCBI
4	Graham DY, Malaty HM and Goodgame R: Primary amino-bisphosphonates: A new class of gastrotoxic drugs - comparison of alendronate and aspirin. Am J Gastroenterol. 92:1322–1325. 1997.PubMed/NCBI
5	Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K and Akune T: Cohort profile: Research on osteoarthritis/osteoporosis against disability study. Int J Epidemiol. 39:988–995. 2010. View Article : Google Scholar : PubMed/NCBI
6	Nagasue T, Nakamura S, Kochi S, Kurahara K, Yaita H, Kawasaki K and Fuchigami T: Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion. 91:37–41. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y and Chiba T: Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 41:452–458. 1997. View Article : Google Scholar : PubMed/NCBI
8	Fujiwara Y and Arakawa T: Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 44:518–534. 2009. View Article : Google Scholar : PubMed/NCBI
9	Malfertheiner P, Fass R, Quigley EM, Modlin IM, Malagelada JR, Moss SF, Holtmann G, Goh KL, Katelaris P, Stanghellini V, et al: Review article: From gastrin to gastro-oesophageal reflux disease - a century of acid suppression. Aliment Pharmacol Ther. 23:683–690. 2006. View Article : Google Scholar : PubMed/NCBI
10	Abrahamsen B, Eiken P and Eastell R: Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 171:998–1004. 2011. View Article : Google Scholar : PubMed/NCBI
11	Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, et al: Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research: Diagnostic criteria for primary osteoporosis: Year 2000 revision. J Bone Miner Metab. 19:331–337. 2001. View Article : Google Scholar : PubMed/NCBI
12	Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, et al: Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut. 45:172–180. 1999. View Article : Google Scholar : PubMed/NCBI
13	Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, et al: Development and evaluation of FSSG: Frequency scale for the symptoms of GERD. J Gastroenterol. 39:888–891. 2004. View Article : Google Scholar : PubMed/NCBI
14	Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, et al: The Alendronate Phase III Osteoporosis Treatment Research Group: A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int. 10:183–192. 1999. View Article : Google Scholar : PubMed/NCBI
15	Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, et al: Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: A double-blind, randomized study. J Bone Miner Metab. 23:382–388. 2005. View Article : Google Scholar : PubMed/NCBI
16	Sipponen P and Härkönen M: Hypochlorhydric stomach: A risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol. 45:133–138. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yang YX, Lewis JD, Epstein S and Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 296:2947–2953. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kaye JA and Jick H: Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 28:951–959. 2008. View Article : Google Scholar : PubMed/NCBI
19	Penning-van Beest FJ, Goettsch WG, Erkens JA and Herings RM: Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis. Clin Ther. 28:236–242. 2006. View Article : Google Scholar : PubMed/NCBI
20	Tuukkanen J and Väänänen HK: Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 38:123–125. 1986. View Article : Google Scholar : PubMed/NCBI
21	Mattsson JP, Väänänen K, Wallmark B and Lorentzon P: Omeprazole and bafilomycin, two proton pump inhibitors: Differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1065:261–268. 1991. View Article : Google Scholar : PubMed/NCBI
22	Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC and Porras AG: Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 58:288–298. 1995. View Article : Google Scholar : PubMed/NCBI
23	Itoh S, Sekino Y, Shinomiya K and Takeda S: The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 31:206–211. 2013. View Article : Google Scholar : PubMed/NCBI
24	Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T and Ogawa N: Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int. 54:370–376. 1994. View Article : Google Scholar : PubMed/NCBI
25	Shikari M, Kushida K, Yamazaki K, Nagai T, Inoue T and Orimo H: Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: A placebo-controlled, double-blind prospective study. Endocr J. 43:211–220. 1996. View Article : Google Scholar : PubMed/NCBI
26	Yoshimura M, Nagahara A, Ohtaka K, Shimada Y, Asaoka D, Kurosawa A, Osada T, Kawabe M, Hojo M, Yoshizawa T, et al: Presence of vertebral fractures is highly associated with hiatal hernia and reflux esophagitis in Japanese elderly people. Intern Med. 47:1451–1455. 2008. View Article : Google Scholar : PubMed/NCBI
27	Yamaguchi T, Sugimoto T, Yamada H, Kanzawa M, Yano S, Yamauchi M and Chihara K: The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporos Int. 13:331–336. 2002. View Article : Google Scholar : PubMed/NCBI
28	Miyakoshi N, Kasukawa Y, Sasaki H, Kamo K and Shimada Y: Impact of spinal kyphosis on gastroesophageal reflux disease symptoms in patients with osteoporosis. Osteoporos Int. 20:1193–1198. 2009. View Article : Google Scholar : PubMed/NCBI